Advertisement
News
Advertisement

MRSA-focused biotech Excelimmune raises $10.5M

Tue, 05/31/2011 - 5:36am
Mass High Tech: The Journal of New England Technology

Excelimmune Inc. announced Tuesday it has closed its Series B financing at $10.5 million – funding that will be used to advance the company’s drug candidate to treat methicillin-resistant Staphylococcus aureus (MRSA).

The Woburn-based company said the funding comes from “a syndicate of new and existing high net worth individual investors,” who were not named.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading